<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03737162</url>
  </required_header>
  <id_info>
    <org_study_id>china subclavian</org_study_id>
    <nct_id>NCT03737162</nct_id>
  </id_info>
  <brief_title>Bare-metal Stent vs Covered Stent in Chinese Patients With Subclavian Occlusive Lesions</brief_title>
  <acronym>BASELINE</acronym>
  <official_title>Bare-metal Stent vs Covered Stent in Chinese Patients With Subclavian Occlusive Lesions: Prospective, Multiple Center, Randomized, Open, Positive Controlled Trail</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xuanwu Hospital, Beijing</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Affiliated Hospital of Dalian Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xinhua Hospital, Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shanghai Changzheng Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital Xi'an Jiaotong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Xuanwu Hospital, Beijing</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Bare-metal stent vs Covered stent with subclavian occlusive lesions to verify the efficacy&#xD;
      and safety.Study Design are prospective, multiple center, randomized, open, positive&#xD;
      controlled, non-inferiority trail.Case total numbers enrollment predict 408 cases，each group&#xD;
      204 cases.Follow up period for 1 years.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">April 2, 2018</start_date>
  <completion_date type="Anticipated">July 3, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 3, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>target lesion patency rate（%）</measure>
    <time_frame>1 years</time_frame>
    <description>12-month target lesion patency rate（%）</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Surgery success rate</measure>
    <time_frame>1 day</time_frame>
    <description>Surgery success rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of complications</measure>
    <time_frame>30 days</time_frame>
    <description>Rate of complications within 30 days；</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of myocardial infarction</measure>
    <time_frame>30 days</time_frame>
    <description>Incidence of myocardial infarction at 30 days follow up；</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ipsilateral stroke and death rates</measure>
    <time_frame>30 days</time_frame>
    <description>Ipsilateral stroke and death rates at 30 days follow up；</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bilateral stroke and death rates</measure>
    <time_frame>30 days</time_frame>
    <description>Bilateral stroke and death rates at 30 days follow up；</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subclavian artery restenosis rate</measure>
    <time_frame>6、12 months</time_frame>
    <description>Subclavian artery restenosis rate at 6、12 months follow up；</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of composite endpoints of myocardial infarction, stroke, and any death</measure>
    <time_frame>30days</time_frame>
    <description>Incidence of composite endpoints of myocardial infarction, stroke, and any death at 30 days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of composite endpoints of myocardial infarction, stroke, and any death</measure>
    <time_frame>6 months</time_frame>
    <description>Incidence of composite endpoints of myocardial infarction, stroke, and any death at 6 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of composite endpoints of myocardial infarction, stroke, and any death</measure>
    <time_frame>12 months</time_frame>
    <description>Incidence of composite endpoints of myocardial infarction, stroke, and any death at 12 months</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical time</measure>
    <time_frame>Through hospital stay，an average of 10 days</time_frame>
    <description>Surgical time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization days</measure>
    <time_frame>Through hospital stay，an average of 10 days</time_frame>
    <description>Hospitalization days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization fees</measure>
    <time_frame>Through hospital stay，an average of 10 days</time_frame>
    <description>Hospitalization fees</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">408</enrollment>
  <condition>Subclavian Occlusion</condition>
  <arm_group>
    <arm_group_label>Covered stent group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Covered stent</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bare-metal stent group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bare-metal stent</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Stent implantation of subclavian artery</intervention_name>
    <description>Stent implantation of subclavian artery</description>
    <arm_group_label>Bare-metal stent group</arm_group_label>
    <arm_group_label>Covered stent group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age≥50 years，sex unlimited；&#xD;
&#xD;
          2. Left subclavian artery disease；&#xD;
&#xD;
          3. The cause of clinical considerations is arteriosclerosis ；&#xD;
&#xD;
          4. The presence of target organ ischemic symptoms, ie dizziness, headache, transient&#xD;
             ischemic attack (TIA), stroke, or other related neurological symptoms caused by&#xD;
             ischemia of the vertebral artery in the past 6 months, or the presence of arterial&#xD;
             stenosis beyond the upper extremity limb ischemia symptoms subclavian；&#xD;
&#xD;
          5. The patient understands the trial objective, understands and accepts the duration of&#xD;
             the study，is able and willing to comply with all requirements，including follow-up and&#xD;
             evaluation of it, voluntarily participates in the study and signs Informed Consent&#xD;
             Form.&#xD;
&#xD;
             Anatomy Criteria&#xD;
&#xD;
          6. Subclavian artery independent disease（Do not merge carotid or vertebral artery disease&#xD;
             ）；&#xD;
&#xD;
          7. Subclavian artery satisfies one of the following criteria：&#xD;
&#xD;
               1. a) Ultrasonography suggests stenosis ≥ 70%，or CT ANGIOGRAM / angiography showed&#xD;
                  stenosis ≥ 70%；&#xD;
&#xD;
               2. Iconography examination confirmed vertebral artery steals；&#xD;
&#xD;
               3. Length of lesion is not involved in vertebral artery opening；&#xD;
&#xD;
               4. Lesions in subclavian artery the beginning portion；&#xD;
&#xD;
          8. The stent can reach the site of lesion smoothly as expected.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with anesthesia contraindications；&#xD;
&#xD;
          2. Serious ipsilateral stroke occurred in the past and may confuse the judgment of the&#xD;
             study endpoint ；&#xD;
&#xD;
          3. Patients with severe dementia ；&#xD;
&#xD;
          4. Patients with spontaneous intracerebral hemorrhage in the past 12 months ；&#xD;
&#xD;
          5. Patients stroke episodes recently， CT or MRI suggested that the lesion is large，and&#xD;
             may be with the risk of hemorrhagic transformation ；&#xD;
&#xD;
          6. Large size of cerebral infarction or myocardial infarction occurred within 30 days ；&#xD;
&#xD;
          7. Patients with large intracranial aneurysms (diameter&gt; 5mm)，and cannot be treated in&#xD;
             advance or contemporaneous ；&#xD;
&#xD;
          8. Chronic total occlusion without obvious cerebral ischemia symptoms ；&#xD;
&#xD;
          9. Patients with hemorrhagic transformation of cerebral arterial thrombosis within 60&#xD;
             days before surgery ；&#xD;
&#xD;
         10. Hemoglobin &lt;100 g/l， Platelet count &lt;125×109/L， INR&gt;1.5， Bleeding time &gt; 1&#xD;
             min，patients with exceeding the upper limits of normal，or heparin-related&#xD;
             thrombocytopenia ；&#xD;
&#xD;
         11. Patients unable to perform normal angiographic evaluation or unsafe percutaneous&#xD;
             puncture poin；&#xD;
&#xD;
         12. Patients with neurologic disorder that caused transient or permanent neurological&#xD;
             deficits within 2 years before the surgery and can not be identified with TIA or&#xD;
             stroke ；&#xD;
&#xD;
         13. Patients with other cardiac emboli sources, such as left ventricular aneurysm,&#xD;
             intraluminal filling defect, cardiomyopathy, aortic or mitral prosthetic heart valve,&#xD;
             calcific aortic stenosis, infective endocarditis, mitral stenosis, atrial septal&#xD;
             defect, atrial septal aneurysm, or left atrial myxoma；&#xD;
&#xD;
         14. Surgical contraindications or patients with high risk of surgery defined as having any&#xD;
             of the following；It is known that two or more proximal or main coronary artery&#xD;
             stenosis ≥70%, untreated or unable to pass；Ejection fraction &lt;30% or New York Heart&#xD;
             Association (NYHA) functional class III or higher；Unstable angina，ie angina at resting&#xD;
             state and electrocardiogram changes；Currently waiting main organ transplants (ie&#xD;
             heart, lung, liver, kidney), or are doing relevant evaluate；Malignant tumor or&#xD;
             respiratory insufficiency, life expectancy &lt; 5 years or FORCED EXPIRATORY VOLUME AT&#xD;
             ONE SECOND &lt; 30% (predicted)；Dialysis-dependent renal failure； Need to perform other&#xD;
             general anesthesia during the same period ；&#xD;
&#xD;
         15. There may be one or more anatomical conditions affecting the normal operative approach&#xD;
             in patients； there may be one or more anatomic situations to increase the risk of&#xD;
             adverse events in patients with high operative risk；including： Neck radiation therapy&#xD;
             history； Radical neck surgery history；Subclavian artery dissection；Lesions&#xD;
             series；Severe long segment calcification of the subclavian artery and severe stenosis&#xD;
             or occlusion of the basilar artery；Inaccessible lesions by endoluminal methods (Severe&#xD;
             distortion of the aortic arch branch, no suitable introduction of arteries, aortic&#xD;
             arch anatomy special）；&#xD;
&#xD;
         16. Investigators consider the patient inappropriate to participate in this clinical&#xD;
             trial；&#xD;
&#xD;
         17. Those who participated in clinical trials of other drugs or medical devices before the&#xD;
             inclusion did not reach the end of the time limit.&#xD;
&#xD;
         18. Rheumatic immune diseases, such as Takayasu arteritis.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>YongQuan Gu YQ Gu, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Xuanwu Hospital, Beijing</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>YongQuan Gu YQ Gu, Prof.</last_name>
    <phone>+8615901598209</phone>
    <email>guyongquan@xwhosp.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>JianMing Guo JM Guo</last_name>
    <phone>+8613146369562</phone>
    <email>guojianming@aliyun.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking hospital first University</name>
      <address>
        <city>Beijing</city>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>YingHua Zou YH Zou, Prof.</last_name>
      <phone>+8613801105222</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The first affiliated Hospital of Dalian Medical University</name>
      <address>
        <city>Dalian</city>
        <zip>116000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Feng Wang F Wang, Prof.</last_name>
      <phone>+8613998642840</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Changhai Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>ZhiQing Zhao ZQ Zhao, Prof.</last_name>
      <phone>+8613301617866</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Changzheng Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>LeFeng Qu LF Qu, Prof.</last_name>
      <phone>+8618616505267</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital affiliated to Fudan University</name>
      <address>
        <city>Shanghai</city>
        <zip>200000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>DaQiao Guo DQ Guo, Prof.</last_name>
      <phone>+8613801785258</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>The first affiliated Hospital of Xi ' an Jiaotong University</name>
      <address>
        <city>Xi'an</city>
        <zip>710000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>JianLin Liu JL Liu, Prof.</last_name>
      <phone>+8613709250539</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2018</verification_date>
  <study_first_submitted>November 6, 2018</study_first_submitted>
  <study_first_submitted_qc>November 8, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2018</study_first_posted>
  <last_update_submitted>November 8, 2018</last_update_submitted>
  <last_update_submitted_qc>November 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">November 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Xuanwu Hospital, Beijing</investigator_affiliation>
    <investigator_full_name>Yong-Quan Gu</investigator_full_name>
    <investigator_title>Prof.</investigator_title>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

